Search Results

At a molecular level, different ligands bind to the same receptor and vice-versa (Marcuzzi et al. 2018 Drug discovery is shifting towards the development of biased ligands, which promote the engagement of and signaling patterns, by modulating ligand binding, as well as G-protein coupling or interaction with , unlike most of the class A GPCRs ligands that are small molecules or short peptides. Overall, the future potential lies in using different therapeutic modalities to modulate the stromal

GPCR dimers in drug discovery referring to important conformational changes, allosteric properties, ligand Interestingly, the amplitude of the conformational changes due to ligand binding is limited at these Li, et al 2012; B. Bai, et al. 2014; B. Ji, et al. 2020; L. Wan, 2020). Various studies reported that the biased properties of ligands and receptors are a consequence of GPCR Junke Liu et al. recently provided key insights into GPCR oligomerization and biased signalling, using

Structurally they characterize by a long extracellular region of adhesion-like domains which modulate structures provided the basis for the mechanism of self-activation of aGPCRs supporting the encrypted ligand possible to know that ADGRL3 can activate and form stable complexes with Gs, Gi, Gq, and G12, where like binding pocket and helps to stabilize the tethered ligand-receptor. Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,

N-terminal PTMs on chemokine receptors The interaction of chemokine receptors with their cognate chemokine ligands This PTM has been shown to be heterogeneous [Li X et al. 2018; Scurci I et al. 2021) and to improve the From the five GalNAc-Ts, GalNAc-T1 was shown to be the most likely candidate for directly glycosylating pairs and potentially cell line and tissue tested. In addition, tyrosine sulfation is heterogenous between cell lines or even on the same cell (Scurci I

Space is limited to 50 scientists. Food and one drink ticket included. Cash bar available. cryo-EM capabilities, including epitope mapping and structure determination of challenging targets like conversation with their CSO Giovanna Scapin Revvity | Founding Co-Host Revvity is a global leader in life Their deorphanisation track record (17 identified natural receptor-ligand pairs) speaks to the depth Space is limited to 50 scientists — registration is required.

Five live Masterclasses are scheduled before summer break. Two Partner Webinars are lining up. Explore the library ➤ Five Live GPCR Masterclasses Before Summer All included in Premium , each one a More live Masterclasses coming in the fall. Premium members have full access to the pre-summer Masterclass lineup, the live sessions, and the expanding on-demand library.

agenda highlights, who's attending, our exclusive discount code, and speaker interviews as they go live include: Abalone Bio  ·  AbbVie  ·  Biagon  ·  Biolexis Therapeutics  ·  Confo Therapeutics  ·  Eli Lilly day brings together teams from Nabla Bio, Abalone Bio, Biagon, Iambic Therapeutics, Lembas, and Eli Lilly

Join us live, April 9, 2026, 10 am EST. Join us live, April 16, 2026, 10 am EST. Read analysis ➤ Computational descriptions of ligand bias remain central to linking structural motion Explore the library ➤ What Members Say “Dr. Library, alongside curated research and industry updates.

Biased signaling frameworks centered on receptor conformations have a structural limitation when selectivity Both layers are examined in the April live sessions with our expert instructors. discussion ➞ Premium Members get live access, full replay, and year-round ecosystem access. From the Masterclass Library This week's featured course from the Masterclass Library: GPCR Projects: Premium members access the full Masterclass library, weekly curated publications, live sessions, and

recognized: the specificity and reliability of anti-GPCR antibodies, and the downstream impact these limitations requires continued attention to antibody specificity, validation strategies, and transparent discussion of limitations By explicitly acknowledging these challenges, the partnership aligns with broader efforts across the life sciences to improve data reproducibility by addressing limitations at the level of research tools.

It is always ligand × system. In the full lecture, Dr. True receptor selectivity must transcend the cell line. A “silent” ligand may be system-limited. More often, one ligand is partial. Now EC₅₀ values alone are insufficient. Terry Kenakin, monthly live AMAs, and a growing on-demand library built for scientists who need clarity

What feels like momentum can quietly become dilution. More programs. Broader roadmaps. What Strategic Discipline Actually Looks Like in Practice Strategic discipline does not mean shrinking look for ambition that is ambitious but engineered. ✅ In other words, strategic discipline does not limit If it does not clearly move the company toward the next decisive milestone, it likely dilutes attention

👉 In early-stage biotech, activity often feels like strategy. On the surface, this looks like a strength. There is movement across the board. Capital is limited. Leadership attention is stretched. Internally, this feels like diversification. Letting go of a program can feel like abandoning potential value.

action, including cAMP accumulation, β-arrestin recruitment, receptor internalization, calcium flux, and ligand With over 180 podcast episodes , live and on-demand educational programs, and a growing partner ecosystem

. 👉 They avoid revisiting earlier decisions because reversing them feels like admitting failure.

This Week in Premium: Sneak Peek Industry insights: Confo nominates SSTR5 agonist antibody CFTX-2034; Lilly Legacy courses will migrate into this format over the coming weeks, with live courses returning in March What you gain: Detect scaffold liabilities early—hERG inhibition, mutagenicity, and mechanistic red flags Since launch, Terry’s Corner has expanded to 30+ courses and three live AMAs covering binding, kinetics An upcoming live Ask-Me-Anything (AMA) with Dr. Kenakin takes place February 26 at 12:00 PM EST.

In early-stage biotech, fundraising rarely feels like a strategic threat. It feels like a necessary distraction. Strategic debate is compressed into slide-friendly conclusions. 👉 What looks like alignment is often

In early-stage drug discovery, one miscalculated liability can bring an otherwise promising scaffold The pressure mounts further as regulators require detection and characterization of these liabilities—even Kenakin reveals how decision-making on early safety hinges on the ability to pinpoint liabilities—such Hepatotoxicity: The Central Organ Challenge The liver, often receiving the highest concentration of Kenakin, monthly live AMAs, and a growing library of on-demand content—all focused on sharpening discovery

Latest breakthroughs :  Lilly confirms Q4 2025 results call; Novo Nordisk explores monthly GLP-1 acquisition Listeners will gain perspective on: Assay choice as strategy , not convenience. Leadership decisions  that keep multidisciplinary teams aligned. 👉 Listen to the full conversation ➤

Even compounds with pristine target profiles can fail in vivo due to poor absorption, limited tissue Drug-Like Properties: The Real Starting Point PK does not begin at dosing—it begins with physicochemical Transporter affinity and solubility limits routinely sabotage otherwise strong ligands Effective PK Kenakin introduces mass-balance thinking and metabolic accounting  to proactively manage liabilities your fingertips : Explore the full library ➤

They emphasize different elements depending on who is listening, which creates confusion instead of clarity This puts the burden of synthesis on the listener , who may not share the same context or priorities. External conversations become easier because the listener understands what they are being asked to evaluate When that decision is made explicitly, depth stops being a liability. They respond to questions as they arise, adjusting emphasis depending on who is listening.

If you have ever wondered why effort does not always translate into results, the answer often lives much Tradeoffs have already been accepted. 👉 What looks like a performance gap late in the year is often What once felt like optionality quietly turns into constraint. This is the phase where choices feel lightweight, but their impact is anything but. With alignment, execution starts to feel lighter, faster, and more coherent.

. 👉 Strong resumes feel like protection against uncertainty. What Survival Traits Look Like in Real Biotech Work 👉 When founders start paying attention, they realize In teams working on complex biology like GPCR targets, this kind of drift is not unusual. matter in early-stage biotech environments. 1️⃣ How candidates describe moments without clear answers: Listen

Complexity feels like progress. At this stage, failure does not look like failure. It looks like motion. Additional data feels like risk reduction, even when it does not change the strategic picture. Teams are no longer sure what success looks like. 👉 No single decision breaks the company, but the absence business reality. ✅ At its core, this is what a functional strategy provides: 1️⃣ Clear priorities that limit

Slides list filings and dates, but do not explain how those rights support the fundraising narrative control that feel unclear or constrained This gap appears most often in academic spinouts, but it is not limited Typical problem areas include: 👉 University licenses with complex or restrictive terms 👉 Unclear rights Founders are expected to show awareness of constraints and options ✅ Looking toward 2026, this trend is likely They can explain what the IP protects, where its limits are, and how that fits the company's direction

. 👉 What it usually looks like: Weekly priorities shift based on whoever raised the loudest concern. That’s the danger. 👉 From the inside, however, it creates a quiet drift: lots of activity, little compounding investor messaging drifts Timelines become aspirational rather than operational ✅ What “good” looks like teams working with partial context narrative inconsistency across stakeholders ✅ What “good” looks like , not momentum Scientific surprises hit harder because the system has no buffer ✅ What “good” looks like

Tracer concentration, receptor density, equilibrium assumptions, and ligand kinetics all influence whether Already available in Terry’s Corner: 30 in-depth lessons and 3 live AMAs  spanning binding, kinetics, probes, fluorescence-based assays, and why availability can matter as much as discovery itself. 🎧 Listen This year brought 20+ podcast episodes, 40% audience growth, and an 811% increase in new listeners. 👉 Access this week’s full Premium Edition here ➤ Voice of the Community “It’s like being at a GPCR

. 👉 The uncomfortable truth: your company is doing a lot of science and very little building. in real life: Meetings end with explanations, not decisions BD calls “went great,” but nothing moves From the outside, it looks like ambiguity. Strategic Takeaway - Why Traction Slips Scientific isolation doesn’t feel like a mistake. It feels like focus.

JB short-circuits that anxiety with a single line he’s used for years: “Hi, I’m JB. His tools exist because he constantly asks: What limitation is chemistry solving here? What limitation is biology solving? For more insight and nuance, listen to the full episode with JB. If JB's story resonates 🎧 Listen to part 1 of this series with Dr.

solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like Founders who prepare to present  often miss the deeper expectation: the FDA is not just listening, it What the FDA Is Actually Optimizing For 👉 Biotech teams often treat the FDA like an evaluator. In reality, the FDA acts more like a systems-level risk assessor . indication selection to study design, should be filtered through the question: “What would this look like